Search

Author/Creator Wilbur, Jayson D.

1. Phase 1 Study to Evaluate the Effect of the Investigational Anticancer Agent Sapanisertib on the QTc Interval in Patients With Advanced Solid Tumors. Issue 7 (2nd June 2020)

Authors:
Patel, Chirag; Goel, Sanjay; Patel, Manish R.; Rangachari, Lakshmi; Wilbur, Jayson D.; Shou, Yaping; Venkatakrishnan, Karthik; Lockhart, A. Craig
Journal:
Clinical pharmacology in drug development
Issue:
Volume 9:Issue 7(2020)
Page Start:
876
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Vedolizumab Efficacy Exposure‐Response Relationship for Ulcerative Colitis Patients (GEMINI I) Based on Causal Inference Analysis: 640. (October 2016)

Authors:
Osterman, Mark; Gastonguay, Marc R.; Lasch, Karen; Barocas, Morris A.; Rosario, Maria; Wilbur, Jayson D.; Dirks, Nathanael L.
Journal:
American journal of gastroenterology
Issue:
Volume 111(2016)Supplement
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Vedolizumab exposure levels and clinical outcomes in ulcerative colitis: determining the potential for dose optimisation. Issue 4 (20th January 2019)

Authors:
Osterman, Mark T.; Rosario, Maria; Lasch, Karen; Barocas, Morris; Wilbur, Jayson D.; Dirks, Nathanael L.; Gastonguay, Marc R.
Journal:
Alimentary pharmacology & therapeutics
Issue:
Volume 49:Issue 4(2019)
Page Start:
408
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗